by Clinical Neuropsychologist Online | Thursday, March 7, 2024 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Mari L. DeMarco, Alicia Algeciras‐Schimnich, Melissa M....
by Clinical Neuropsychologist Online | Wednesday, March 6, 2024 | Dementia
Abstract INTRODUCTION Tau phosphorylated at threonine-217 (pT217-tau) is a novel fluid-based biomarker that predicts onset of Alzheimer’s disease (AD) symptoms, but little is known about how pT217-tau arises in the brain, as soluble pT217-tau is dephosphorylated...
by Clinical Neuropsychologist Online | Wednesday, March 6, 2024 | Paediatric Neuropsychology
Volume 13, Issue 2, April-June 2024, Page 180-189. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Tina ThomasJulie A. GriecoMargaret PulsiferMassachusetts...
by Clinical Neuropsychologist Online | Wednesday, March 6, 2024 | Dementia
Dementia, Volume 23, Issue 4, Page 643-668, May 2024. IntroductionHealth research that focuses on Indigenous Peoples must ensure that the community in question is actively engaged, and that the results have context relevance for Indigenous Peoples. Context relevance...
by Clinical Neuropsychologist Online | Tuesday, March 5, 2024 | Dementia
Abstract INTRODUCTION Magnetic resonance imaging (MRI) biomarkers are needed for indexing early biological stages of Alzheimer’s disease (AD), such as plasma amyloid-β (Aβ42/40) positivity in Aβ positron emission tomography (PET) negative individuals. METHODS...
